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Abstract
Background: Patients with symptomatic internal carotid artery (ICA) or middle cerebral artery (MCA) occlusion with
haemodynamic insufficiency are at high risk for recurrent stroke when treated medically.
Methods: The Carotid or Middle cerebral artery Occlusion Surgery Study (CMOSS) trial is an ongoing, government-
funded, prospective, multicentre, randomised controlled trial. The CMOSS will recruit 330 patients with symptomatic
ICA or MCA occlusion (parallel design, 1:1 allocation ratio) and haemodynamic insufficiency. Participants will be
allocated to best medical treatment alone or best medicine plus extracranial-intracranial (EC-IC) bypass surgery.
The primary outcome events are all strokes or deaths occurring between randomisation and 30 days post operation
or post randomisation and ipsilateral ischaemic stroke within 2 years. Recruitment will be finished by December
2016. All the patients will be followed for at least 2 years. The trial is scheduled to complete in 2019.
Discussion: The CMOSS will test the hypothesis that EC-IC bypass surgery plus best medical therapy reduces
subsequent ipsilateral ischaemic stroke in patients with symptomatic ICA or MCA occlusion and haemodynamic
cerebral ischaemia. This manuscript outlines the rationale and the design of the study. CMOSS will allow for more
critical reappraisal of the EC-IC bypass for selected patients in China.
Trial registration: NCT01758614 with ClinicalTrials.gov. Registered on 24 December 2012.
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Background
Patients with symptoms of cerebral ischaemia associated
with ipsilateral internal carotid artery (ICA) occlusion
have an annual risk of 5–8% of recurrent ischemic stroke
[1, 2]; patients with symptomatic middle cerebral artery
(MCA) disease (including severe stenosis and occlusion)
have an overall stroke risk of 12.5% per year (ipsilateral:
9.1%) [3]. The annual risks of recurrent ischaemic stroke
in patients with symptomatic ICA or MCA occlusion
have not obviously improved over recent years [4]. The
proportion of recurrence with minor disabling conse-
quences was rather high.
The pathophysiology of carotid and middle cerebral
artery occlusion
Collateral circulation
Compensation by a collateral circulation is usually
considered important in the pathophysiology of cere-
brovascular stenosis and occlusion. The Circle of Willis
as the primary collaterals provides immediate diversion
of cerebral blood flow (CBF) to ischaemic regions. The
compensatory capacity of the primary collaterals
depends on their vascular calibre and patency. The
ophthalmic artery and leptomeningeal vessels consti-
tute secondary collaterals, and also contribute ancillary
collateral flow to distal segments of stenotic or oc-
cluded major cerebral arteries [5]. In a case of occlusion
of the ICA or MCA over a chronic time course, the fea-
tures of the secondary collaterals are related to the
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severity of haemodynamic alterations and metabolic
and neuroendocrine mechanisms [5].
Patterns of collateral flow in chronic occlusive cerebro-
vascular disease are different between the ICA and the
MCA [6, 7]. In patients with ICA occlusion, possible
compensatory blood flow could be from the contralateral
ICA via the anterior communicating artery (AComA) or
from the vertebrobasilar system via the posterior commu-
nicating artery (PcomA). While anatomic studies show
that about 1% of subjects have an absent AComA, 10% of
subjects have an absent or hypoplastic proximal anterior
cerebral artery and 30% of subjects have absence or hypo-
plasia of one or other PComA [8].
Because the MCA is located in the downstream of the
Circle of Willis, the primary collaterals fail to compensate
for the loss of blood flow perfusion; only pial or meningeal
to pial collaterals are available in patients with MCA
occlusion [6, 7]. However, the pial collaterals are not ad-
equate to maintain normal cerebral haemodynamics.
Thus, poor collateral development is considered a risk
factor for stroke in patients with MCA occlusion [6, 7.]
Additionally, the development of a collateral circula-
tion does not guarantee its function and its function
may be related to age, comorbidities and the duration of
ischaemia [9]. Haemodynamics is one of the most im-
portant factors [7].
Cerebral haemodynamics
The haemodynamic stroke is a kind of stroke subtype
caused by local or systemic hypoperfusion. Occlusion of
the ICA or MCA is the local factor that contributes to im-
paired haemodynamics although low blood pressure (BP)
or volume might also play a systemic role [10]. According
to cerebrovascular autoregulatory mechanisms, CBF could
remain static during steady-state changes in cerebral per-
fusion pressures (CPPs) within a wide range by the occur-
rence of distal vasodilation. Vasomotor reactivity (VMR)
or cerebral vasoreactivity (CVR) is used to describe this
capability of cerebral resistance arterioles to change their
calibre when CPPs decrease. Decreased VMR indicates
preexisting vasodilation induced by ICA or MCA occlu-
sion. When distal vasodilation becomes maximal and
CPPs continue to decline, the brain tissue increases the
oxygen extraction from the blood in order to maintain
normal metabolism and function [11]. That is termed
‘misery perfusion’ or stage II haemodynamic compromise
[10]. There is increasing evidence that cerebral haemo-
dynamics play an important role in the long-term progno-
sis of patients with chronic ICA or MCA occlusion. Some
investigators report that the annual risk of ipsilateral
stroke is 32.7% in ICA occlusion patients with impaired
VMR and poor collateral circulation [4]. Derdeyn et al.
also demonstrated that in patients with MCA occlusion,
the frequency of impaired haemodynamic compromise
was high [12]. So patients in these situations might benefit
from revascularisation surgery.
Cerebral haemodynamic evaluation
Cerebral haemodynamic evaluation is the core factor
for patients with ICA or MCA occlusion. Quantitative
xenon-computed tomography-(CT) can provide exact
data of regional CBF and, accompanied with the Dia-
mox challenge test, can determine the VMR/CVR
convincingly [13]. Xenon-CT with the Diamox chal-
lenge test has been utilised widely in Japan and the
USA, while recently the spread of its usage across the
world has been slowed down because of the current
limitations in access of FDA.
[15O]H2O positron emission tomography (PET) not
only provides quantitative CBF values, but also
cerebral metabolism information. As the basis of the
Carotid Occlusion Surgery Study (COSS) funded by
the NIH (National Institutes of Health), the St. Louis
Carotid Occlusion Study (STLCOS) was performed in
order to evaluate the cerebral haemodynamics of pa-
tients with ICA occlusion systematically using PET
[11]. Using a semiquantitative, count-based hemi-
spheric oxygen extraction fraction (OEF) ratio
method, STLCOS first identified the normal OEF ra-
tio threshold from normal control subjects. The risk
of all strokes was then found to be 6.0 times higher
in patients with stage II haemodynamic failure (with
increasing OEF) compared to normal OEF, and the
risk of ipsilateral stroke was 7.3 times higher. Unfor-
tunately, because different countries have different sit-
uations, [15O]H2O PET is still limited in many
countries, especially in developing countries, because
access to [15O] requires an on-site cyclotron.
With the spread of modern computed tomography
(CT) scanners, the CT perfusion (CTP) technique is
easily available in most institutes. Remarkable develop-
ments have been achieved in perfusion techniques even
though measurement variability (precision) is in the
range of 15–30% when region of interest (ROI)-based
techniques are used [14]. According to the perfusion
technique mechanism, several investigations have tried
to identify the normal thresholds for interpreting mea-
surements made with this technique. Waaijer et al. [15]
identified that the least variability is located in the
MCA territory. Calculation of CTP ratios of bilateral
hemispheres may eliminate the variations caused by
the selection of the arterial input function (AIF) and
venous output function (VOF). If the ROIs drawn in
bilateral hemispheres are symmetrical, CTP ratios will
be helpful to eliminate the resulting measurement
variability. The COSS investigators [16] also tried to
compare CTP with [15O]H2O PET in patients with
chronic ICA occlusion and found mean transit time
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(MTT) to be the best parameter, correlating with the
count-based PET OEF ratios (slope = 0.124, intercept =
0.676, R2 = 0.590, p < 0.001). CTP relative CBF (rCBF)
compares favorably to PET relative CBF when proc-
essed using a dedicated AIF for each territory (R2 =
0.796, p < 0.001). According to these results, a combin-
ation of decreased CBF ratio (symptomatic side/asymp-
tomatic side) and increasing MTT could help to
distinguish stage II haemodynamic failure.
Methods
Trial design
The Carotid or Middle cerebral artery Occlusion
Surgery Study (CMOSS) trial in China is designed to
compare the safety and efficacy of EC-IC bypass sur-
gery with medical therapy in patients with symptomatic
ICA or MCA occlusion (within 120 days). It is the
subproject of the ‘Five-twelfth’ National Science and
Technology Support Program funded by the Chinese
government and is a randomised controlled trial (RCT)
that plans to enroll 330 patients with equal randomisa-
tion to surgical and nonsurgical groups. The allocation
ratio will be 1:1. The CMOSS trial will be conducted in
15 centres in China.
Inclusion and exclusion criteria
Inclusion criteria
(1) Age ranging between 18 and 65 years
(2) Digital subtraction angiography (DSA) imaging
studies demonstrating occlusion of a unilateral
ICA or MCA
(3) DSA studies demonstrating less than 50% stenosis
of any other vessels especially the contralateral ICA,
MCA or basilar artery
(4) Modified Rankin Scale (mRS) score 0–2
(5) A qualifying transient ischaemic attack (TIA) or
ischaemic stroke in the territory of the occluded
ICA or MCA must have occurred within the
past 12 months
(6) The most recent stoke occurred more than
3 weeks previously
(7) The neurological deficit must have been stable
for more than 1 month
(8) No massive cerebral infarction (more than 50%
of the MCA territory) demonstrable in a CT
or magnetic resonance imaging (MRI) study
(9) CTP demonstrates ‘misery perfusion’
(MTT more than 4 s and rCBF
(symptomatic side/asymptomatic side) < 0.95)
(10) Must be competent to give informed consent
(11) Must be legally an adult
(12) Must be geographically accessible and reliable
for follow-up
Exclusion criteria
(1) Other neurovascular disease (such as cerebral
aneurysm or arteriovenous malformation) conditions
likely to cause focal cerebral ischaemia
(2) Known unstable angina or myocardial infarction
within the last 6 months
(3) Pregnant or perinatal stage women
(4) Coagulopathy
(5) Any diseases likely to lead to death within 2 years
(6) Past history of EC-IC bypass surgery
(7) Any contraindications or allergy to aspirin or
clopidogrel
(8) Any heart disease likely to cause cerebral ischaemia
including prosthetic valve(s), infective endocarditis,
atrial fibrillation, sick sinus syndrome, myxoma, and
cardiomyopathy with an ejection fraction of less
than 25%
(9) Allergy to iodine or radiographic contrast media
(10) Serum creatinine level > 3 mg/dl
(11) Uncontrolled diabetes mellitus (fasting blood
glucose level > 16.7 mmol/l)
(12) Uncontrolled hypertension (systolic BP above
180 mmHg, diastolic BP above 110 mmHg)
(13) Severe liver dysfunction (alanine transaminase
(ALT) and/or aspartate transaminase (AST)
more than three times the normal level)
(14) Concurrent participation in any other
experimental treatment trial
(15) Any condition that in the surgeon’s judgment
suggests the patient to be an unsuitable surgical
candidate
Intervention and follow-up
After an Informed Consent Form (ICF) has been signed,
all the patients will be given best medical treatment
including management of risk factors (elevated systolic
BP, elevated low-density lipoprotein cholesterol level, dia-
betes mellitus, smoking, excess weight). Aspirin (100 mg
per day) or clopidogrel (75 mg per day) will be prescribed
to the patient and they will discontinue the use of any
other antithrombotic therapy (specifically, oral anticoagu-
lant agents) until the 30-day follow-up visit. After that, the
experienced neurologists caring for the patient will deter-
mine the necessity of antithrombotic therapy.
Surgical intervention will be performed within 7 days
after randomisation by attending neurosurgeons who
have been certified as chief surgeon in at least 15
consecutive previous EC-IC bypass surgeries. Their sur-
gical record of anastomosis graft patency is greater than
95% and the perioperative stroke and death rate is less
than 10%. Standard end-to-side anastomosis of the
superficial temporal artery (STA) to the M4 segment
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(MCA) will be utilised. If the STA is unsuitable, the
occipital artery may be used.
All the patients will be followed up at the neurological
outpatient clinic on four occasions (at 30 days, 6, 12,
and 24 months). Scheduled follow-up examinations are
summarised in Table 1. If a potential endpoint event oc-
curs, patients will be examined by neurologists within
24 h. If a stroke is suspected, MRI or CT will be per-
formed as soon as possible.
Outcome events and study measures
The primary outcome events will be defined as all
strokes or deaths occurring between randomisation and
the 30-day postoperative time point (for the nonsurgical
group, this will be defined as all strokes or deaths occur-
ring within 30 days post randomisation) and ipsilateral
ischaemic stroke within 2 years post randomisation. A
stroke is defined as rapid loss of neurological function
due to ischaemia or a haemorrhage. Ipsilateral ischaemic
stroke is further defined as the clinical diagnosis of a
focal neurological deficit due to cerebral ischaemia that
is clinically localisable within the territory of the symp-
tomatic occluded ICA or MCA and that lasts for more
than 24 h. CT or MRI scanning is necessary to identify
the stroke.
Secondary outcome events include all strokes, disab-
ling or fatal strokes and deaths between 30 days and
2 years post randomisation; severe TIA; complications
associated with the surgical procedures; mRS score,
National Institutes of Health Stroke Scale score (NIHSS)
and Barthel Index assessment within 2 years; and anasto-
mosis patency and haemodynamic changes within 2 years.
Sample size and randomisation
Sample size assumes that the true primary outcome rates
will be 28% in the medical treatment group [17–19] and
in the surgical group there will be 50% relative risk reduc-
tion. This means that the 2-year postoperative
ipsilateral stroke or death rate was assumed to be 14%
in the surgical group. This would require 264 (132 per
group) participants to provide valid data to ascertain
this endpoint of the study (power of 80% and two-tailed
alpha of 5% significance level). Further anticipation in-
cludes as many as 20% loss to follow-up or early with-
drawal, which would require that 330 participants
enroll in the study (165 per group).
A Central Imaging Evaluation Committee (CMEC) will
review all the image data of every candidate before
randomisation. Subsequently, when a local investigator
receives the permitted information from CMEC, IVRS
(Interactive Voice Response System, Clinicalsoft Company
Table 1 Follow-up schedule
Baseline 7 days 30 days 6 months 12 months 24 months
Neurological function evaluation
NIHSS ✓ ✓ ✓ ✓ ✓ ✓
mRS ✓ ✓ ✓ ✓ ✓ ✓
BI ✓ ✓ ✓ ✓ ✓ ✓
Neuro-imaging evaluation
Brain CT/MRI ✓DWI ✓ ✓ ✓ ✓ ✓
Cerebrovascular CTA/MRA ✓
DSA ✓ ✓a ✓b ✓
CTP ✓ ✓a ✓ ✓ ✓
Medication
Current medication ✓ ✓ ✓ ✓ ✓ ✓
Medication compliance ✓ ✓ ✓ ✓ ✓
Adverse events ✓ ✓ ✓ ✓ ✓ ✓
Physical examination ✓ ✓ ✓ ✓ ✓ ✓
Vital signs ✓ ✓ ✓ ✓ ✓ ✓
Laboratory tests ✓ ✓a ✓ ✓ ✓
Pregnancy test ✓ ✓
Electrocardiogram ✓ ✓
Chest X-ray ✓ ✓
aBypass surgical group only; bIf necessary; CT computed tomography, CTA computed tomography angiography, CTP computed tomography perfusion, DSA digital
subtraction angiography, DWI diffusion-weighted imaging, MRA magnetic resonance angiography, MRI magnetic resonance imaging, mRS modified Rankin scale,
NIHSS National Institutes of Health Stroke Scale
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Limited) will be used for randomisation. Patients will be
randomised (in a 1:1 ratio, with a random permuted block
design (block size 2, 4, or 6) stratified by clinical site) to
medical treatment alone or medical treatment plus bypass




The recently published COSS [20] failed to show a benefit
of EC-IC bypass surgery over medical therapy in patients
with symptomatic haemodynamically significant carotid
occlusion. Since then different controversies [21, 22]
have been raised regarding several aspects of the study
including the study population, the surgeons’ qualifica-
tions, and haemodynamic evaluation.
In the COSS protocol [23], the primary inclusion
population is a patient demonstrating occlusion of the
unilateral ICA with the contralateral ICA demonstrating
less than 50% stenosis. While in the final report, only
18% of patients demonstrated a contralateral ICA sten-
osis of more than 50% because of enrolment problems
[20]. As we know, the COSS utilised the OEF ratio by
PET as the criterion of haemodynamic evaluation. How-
ever, bilateral ICA lesions will disturb this ratio and will
even disturb the identification of the subgroup of pa-
tients with haemodynamic insufficiency.
As an interventional trial, the COSS should ensure the
certification of the experienced surgeons. However, for
expanding the number of centres and enhancing recruit-
ment, the COSS made some concessions on the sur-
geons’ training and certification; the 15% postoperative
event rate is not the best that can be achieved. In a
recently published article about the analysis of mecha-
nisms of perioperative ischaemic stroke by the COSS
investigators [24], they found that the temporary occlu-
sion time of the MCA during the anastomotic procedure
(54.3 ± 23.5 min) was no different from the occlusion
time in those surgical patients who did not sustain a
perioperative stroke (45.4 ± 24.2 min, p = 0.2). Under
the strict intraoperative management protocol and
within the temporary vessel occlusion time, which
ranged from between 25 and 42 min (mean 33.6 ± 7 -
minutes) as used in the study by Horn et al. [25], the
postoperative ischaemic stroke rate should be less than
10%. This discrepancy would suggest that these under-
lying assumptions warrant further exploration and
more rigorous research.
The COSS Kaplan-Meier curve demonstrated a cross-
over benefiting surgery along with follow-up continu-
ation. But, in fact the COSS was terminated early for
‘futility’. However, if all the enrolled patients had
completed the follow-up interview the study might
have had adequate power to show a significant benefit
from surgery by 5 years [26].
Rationale of CMOSS
The CMOSS is the first RCT sponsored by a developing
country to evaluate the efficacy and safety of EC-IC
bypass surgery. It is also the first RCT to evaluate the
cerebrovascular haemodynamics by CTP in patients with
ICA or MCA occlusion. It is well-known that intracra-
nial arterial stenosis or occlusion in Asia is much more
common than in Europe or North America. This could
greatly encourage patient enrolment. The CMOSS also
selects more experienced neurosurgeons to work in the
trial to minimise perioperative complications.
For the sample size calculation, we consulted the
figures for stroke risk from MCA occlusion, which is
different from ICA occlusion. In 1996, Yamauchi et al.
[17] investigated patients with symptomatic ICA or
MCA occlusive diseases. They found that the incidence
of ipsilateral ischaemic strokes in patients with increased
OEF and normal OEF was 57.1% and 6.0%, respectively.
(They also suggested that patients with increased OEF
had decreased CBF and CBF/CBV values.) Kuroda et al.
[19] reported that the annual risks of total and ipsilateral
stroke in patients with ICA or MCA occlusion and
decreased rCBF and relative cerebral vasoreactivity
(rCVR) were 35.6% and 23.7%, respectively. Actually, the
total annual risk of ipsilateral stroke in patients with
decreased rCBF only was 26.1%. In 2002, Ogasawara et
al. [18] presented a study to prospectively evaluate the
relationships between cerebral haemodynamics and out-
come of patients with symptomatic major cerebral artery
occlusion (including ICA and MCA) by quantitative
measurement of CBF using 133Xe and single photon
emission tomography (SPECT). During the follow-up,
the recurrence rate of stroke was 34.7% in patients with
reduced rCVR at entry and less than 6% in patients with
normal rCVR. All these data indicate that the annual
risk of stroke is relatively higher in MCA than in ICA
occlusion. Recently, aggressive medical management has
been more widely used, and according to the results of a
follow-up by our centre over the last 3 years, the risk of
stroke in ICA or MCA occlusion is about 28%, which
conforms to the data mentioned. Compared with the
medical treatment group (28%), a further 50% reduction
in the surgical treatment group is considered to be clin-
ically significant; that is 14%. Regarding perioperative
morbidity, in the COSS [20] the perioperative rate for
ipsilateral ischemic stroke was 14.4%, while the rate for
the primary end point was 21.0%. This indicates that the
stroke rate between 30 days to 2 years was about 7%. In
the CMOSS, we have much stricter licensing of neuro-
surgeons; attending neurosurgeons are certified by their
roles as chief surgeon in at least 15 consecutive previous
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EC-IC bypass surgeries. Using this level of expertise
means that in China we can achieve an anastomosis
graft patency rate of greater than 95% and a periopera-
tive stroke and death rate of less than 10%.
In addition, because of the continuity of the ‘Five-twelfth’
National Science and Technology Support Program, the
follow-up for these patients could prolonged to more than
2 years. This could reveal more information after analysis
of the ‘cross-over curves’ in the COSS.
Trial status
The CMOSS trial is currently recruiting participants.
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